Clinical trial VISION
VISION: An international, prospective, open label, multicenter, randomized Phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
Cancers | |
---|---|
Organ | prostate |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Endocyte |
EudraCT Identifier | 2018-000459-41 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03511664 |
Inclusion criteria | *Must have received at least one NAAD(enzalutamide or abiraterone). *1 or 2 prior treatment with taxane*Progressive disease |
Last update |